14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $43.33 $53.35 Thursday, 2nd May 2024 BMY stock ended at $43.70. This is 1.15% less than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 2.51% from a day low at $43.33 to a day high of $44.42.
90 days $43.33 $55.03
52 weeks $43.33 $69.10

Historical Bristol-Myers Squibb Company prices

Date Open High Low Close Volume
Feb 21, 2024 $49.93 $50.93 $49.54 $50.91 10 201 455
Feb 20, 2024 $49.89 $50.45 $49.67 $49.86 9 866 531
Feb 16, 2024 $49.31 $49.87 $48.93 $49.86 13 165 815
Feb 15, 2024 $49.01 $50.28 $48.83 $49.44 8 217 199
Feb 14, 2024 $48.82 $49.04 $48.45 $48.89 8 329 347
Feb 13, 2024 $49.66 $49.90 $48.31 $48.71 12 364 061
Feb 12, 2024 $49.82 $50.05 $49.21 $49.75 14 942 655
Feb 09, 2024 $48.70 $49.83 $48.49 $49.81 15 384 915
Feb 08, 2024 $48.44 $48.77 $48.11 $48.71 11 200 360
Feb 07, 2024 $49.19 $49.35 $48.03 $48.64 15 097 497
Feb 06, 2024 $47.95 $49.98 $47.58 $49.26 19 680 187
Feb 05, 2024 $48.52 $48.56 $47.68 $47.98 15 523 483
Feb 02, 2024 $49.27 $50.00 $48.08 $48.71 23 140 568
Feb 01, 2024 $48.85 $48.85 $48.13 $48.67 19 235 098
Jan 31, 2024 $49.71 $50.02 $48.84 $48.87 14 043 161
Jan 30, 2024 $50.05 $50.18 $49.25 $49.39 11 505 877
Jan 29, 2024 $49.62 $49.88 $49.45 $49.87 11 677 750
Jan 26, 2024 $49.96 $50.20 $49.65 $49.70 8 708 420
Jan 25, 2024 $50.26 $50.34 $49.44 $49.61 17 262 041
Jan 24, 2024 $50.20 $50.62 $50.07 $50.24 11 699 458
Jan 23, 2024 $49.68 $50.42 $49.49 $50.12 12 445 593
Jan 22, 2024 $50.26 $50.32 $49.50 $49.57 10 709 444
Jan 19, 2024 $50.11 $50.21 $49.43 $50.11 23 070 712
Jan 18, 2024 $49.62 $50.17 $48.63 $50.09 18 456 859
Jan 17, 2024 $49.55 $50.07 $48.95 $49.98 16 404 747
Click to get the best stock tips daily for free!

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for th... BMY Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT